 Cortexyme, Inc. Nasdaq: CRTX, a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with Alzheimers and other degenerative diseases, today announced that the International Nonproprietary Naming Committee of the World Health Organization WHO has selected atuzaginstat pronounced a too za gin stat as the proposed International Nonproprietary Name, or pINN, for the companys lead product candidate COR388. Atuzaginstat is an oral, twice-daily investigational medicine in late stage clinical development for Alzheimers disease that is designed to inhibit lysine gingipain, a virulence factor protease released by P. gingivalis. 